ACDF | HS1 | HS2 | P | |
---|---|---|---|---|
NDI at pre-op | 38.0 ± 3.0 | 38.9 ± 3.9 | 37.9 ± 2.1 | 0.230 |
NDI at 1 week later | 19.3 ± 6.9 | 19.9 ± 4.4 | 19.3 ± 5.1 | 0.875 |
NDI at final follow-up | 12.5 ± 8.2 | 10.7 ± 3.3 | 11.8 ± 2.2 | 0.163 |
Δ1 NDI | 19.0 ± 6.9 | 19.9 ± 5.0 | 18.5 ± 3.7 | 0.792 |
Δ2 NDI | 25.8 ± 8.2 | 28.8 ± 5.6 | 27.2 ± 2.0 | 0.215 |
P1 (NDI) | < 0.001 | < 0.001 | < 0.001 | |
P2 (NDI) | < 0.001 | < 0.001 | < 0.001 | |
P3 (NDI) | < 0.001 | < 0.001 | 0.009 | |
JOA at pre-op | 10.3 ± 1.9 | 11.0 ± 1.7 | 11.3 ± 1.5 | 0.125 |
JOA at 1 week later | 14.6 ± 1.4 | 14.9 ± 0.8 | 15.3 ± 0.5 | 0.433 |
JOA at final follow-up | 15.7 ± 1.9 | 16.2 ± 1.1 | 15.8 ± 1.0 | 0.406 |
RR1 JOA (%) | 63.8 ± 23.5 | 63.4 ± 13.2 | 56.3 ± 18.5 | 0.740 |
RR2 JOA (%) | 81.8 ± 29.4 | 87.0 ± 18.1 | 71.0 ± 21.0 | 0.361 |
P1 (JOA) | < 0.001 | < 0.001 | 0.002 | |
P2 (JOA) | < 0.001 | < 0.001 | 0.001 | |
P3 (JOA) | 0.018 | < 0.001 | 0.456 |